IMUGENE LIMITED (IMU)

Latest AI Signal: SELL
Status: AGING
Days Old: 6

Confidence: 65.00%

Date: 15-05-2026

Price: $0.093

Last Price: $0.094

Post-Signal Low Price: $0.091

Latest  IMUGENE LIMITED(IMU)   News

20 Jul 2023, 10:00 PM

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors LOS ALTOS, Calif. & SYDNEY, July 20, 20

28 Jun 2023, 08:30 PM

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Kineta, Inc. SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to i

06 Apr 2023, 04:30 AM

Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial

Melbourne, Victoria --News Direct-- Imugene Ltd Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that the company has dosed the first patients in cohort three of its intravenous (IV) and intratumoral (IT) monotherapy dose-escalation trial for novel cancer-killing virus VAXINIA (also known as

04 Mar 2023, 03:40 AM

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

Melbourne, Victoria --News Direct-- Imugene Ltd Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intraveno

27 Jan 2023, 08:17 AM

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Celularity, Inc. Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celu

Chart available once enough post-signal price data is available.

Sell Confidence Medium

AI Confidence - 65.00 % model confidence

Business Overview

Imugene Limited is an Australian clinical-stage immuno-oncology company focused on developing novel cancer immunotherapies, including vaccines and oncolytic virus platforms. The company is positioned in the biotech sector with a focus on leveraging immune system mechanisms to treat various cancers, operating in a highly competitive and research-intensive market.

Financial Analysis

Cash Flow	Weak
Debt	Moderate
Profitability	Weak
Revenue Trend	Downtrend

Technical Analysis

Trend	Bearish
Momentum	Weak
RSI Signal	Oversold
Support Level	$ 0.085
Resistance Level	$ 0.11

Valuation

Valuation - Overvalued

Current price reflects high risk and speculative nature of clinical-stage biotech with limited near-term revenue visibility.

Catalysts

• Upcoming clinical trial results or regulatory updates

• Strategic partnerships or licensing deals

• Positive data readouts from pipeline candidates

Recommendation

Action - Sell

Timeframe - Short Term

Given weak financials, bearish technicals, and significant clinical and regulatory risks, the stock is expected to face downward pressure. Investors should consider reducing exposure until clearer positive catalysts emerge.